



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

INTERACTION OF INFLUENZA VIRUS
WITH SWINE ALVEOLAR MACROPHAGES:
INFLUENCE OF ANTI-VIRUS ANTIBODIES
AND CYTOCHALASIN B

by B. Charley

INRA, Laboratoire de Pathologie porcine,
Station de Recherches de Virologie et d'Immunologie,
78850 Thiverval-Grignon (France)

SUMMARY

Interactions between swine influenza virus and swine alveolar macrophages were studied *in vitro*. Cell lysis occurred 24 h post-infection and was shown by a decreased neutral red uptake. UV inactivation of the influenza virus, or the addition of anti-influenza antibodies suppressed the virus-induced macrophage lysis. Inversely, pretreatment of swine alveolar macrophages by a phagocytosis inhibitor, namely cytochalasin B, increased the cell susceptibility to virus-induced lysis.

The present *in vitro* studies support the hypothesis that defects in pulmonary antibacterial mechanisms associated with influenza infections are partly due to a direct toxic effect of the virus on alveolar macrophages. Furthermore, the studies show that virus-induced macrophage lysis is influenced by specific humoral immune responses and by modifications in microfilament cell functions.

KEY-WORDS: Phagocytosis, Influenza virus, Immunomodulation; Alveolar macrophages, Pig, Cytochalasin B, Virus toxicity.

INTRODUCTION

Alveolar macrophages are important elements in the lungs' defence mechanisms against infection, being capable of phagocytosis [30], cell-mediated cytotoxicity [25], interferon production [1] and numerous interactions with the immune system [12]. In the course of an influenza infec-

tion, secondary bacterial pneumonias are often described and are partly explained by impaired functions of the alveolar macrophages; thus, influenza-virus-infected mice showed a reduced rate of inactivation of inhaled bacteria [33] as well as altered alveolar macrophage activities [27, 13]. Quite similar results were obtained with Sendai (parainfluenza 1) virus infection in mice [8, 23, 32]. Most *in vitro* studies have also shown that the influenza virus was able to play direct toxic and antiphagocytic roles on blood leukocytes [28, 20, 14, 4] and on human [31] as well as mouse alveolar macrophages [15, 19]. In alveolar macrophages, the influenza virus replication cycle was found to be abortive [31, 15, 17, 19].

Several groups of workers have tried to modulate interactions between the influenza virus and macrophages by using macrophage activators: a non-specific stimulation, obtained by repeated *i. p.* injections of mice with *Staphylococcus aureus*, rendered peritoneal macrophages more resistant to the influenza virus than cells from normal mice [21]. Similarly, *i. p.* injection of BCG reduced the influenza virus titre within activated peritoneal macrophages as compared to control cells [10].

In order to ascertain whether modulation of phagocytosis could influence *in vitro* interactions between the influenza virus and alveolar macrophages, we compared the effects of virus and virus plus antibody complexes on swine alveolar macrophages and tried to determine if a phagocytosis inhibitor, namely cytochalasin B, would modify the consequences of the viral infection on alveolar macrophages.

MATERIALS AND METHODS

1) Collection of swine alveolar macrophages (SAM).

Collection of SAM by lung washing was performed on sacrificed and exsanguinated pigs as previously described [6]. The lavage fluid obtained was centrifuged (600 *g*, 15 min), and the cell pellet was further washed in Earle-lactalbumin medium supplemented with antibiotics (400 *g*, 10 min.)

2) Influenza virus production and titration.

A/Porc/Paris/1/77 (H₃N₂), analogous to A/Texas/1/77, was isolated in France from pig lungs and kindly provided by Pr C. Hannoun (Institut Pasteur, Paris) [11]. This strain was passaged in the allantoic cavity of embryonated eggs and stored at -70° C. Virus titres were determined by the egg infectivity (EID₅₀: egg infective dose 50 %).

3) SAM cultures, virus infection and neutral red staining.

Broncho-alveolar cells obtained by lung washing were plated in 6-well plastic plates (Costar, 3506, Cambridge, USA): 1.5 × 10⁶ cells per well in 1 ml RPMI-1640

EID₅₀ = egg infective dose 50 %.
 FCS = foetal calf serum.
 OD = optical density.

SAM = swine alveolar macrophage.
 SDS = sodium dodecyl sulphate.
 UV = ultra-violet.

(Flow, Irvine, Scotland), supplemented with 10 % foetal calf serum (FCS), antibiotics and 2 mM glutamine. Following at least 2 h of incubation at 37° C, non-adherent cells were discarded, and SAM were maintained in culture medium (RPMI-1640 with 10 % FCS).

SAM monolayers were exposed to influenza virus for 1 h, washed and incubated for 24-48 h as indicated in « Results ». The residual viable cells were then stained with neutral red as follows: SAM monolayers were incubated at 37° C for 30 min, with 1 ml neutral red (RAL, Biolyon, France) diluted 1/10,000 in Tris-buffered medium (pH 7.4). The supernatant was discarded, and monolayers were washed once more to eliminate the non-ingested dye. Pure ethyl alcohol was then added (1 ml/well) in order to resolubilize intracellular neutral red, and the optical density (OD) of each supernatant was measured at 460 nm.

In order to compare the neutral red staining procedure with a classical viability determination, monolayers were stained with eosin (Gurr, Merck, Paris).

When SAM were pretreated with cytochalasin B (n° C-6762 from Sigma, St. Louis, USA), diluted at 1 mg/ml in 0.1 % DMSO (Fluka, Switzerland), monolayers were incubated at 37° C for 18 h before virus infection. Each assay was performed in triplicate.

4) *Hyperimmune anti-influenza serum.*

A pig was intramuscularly injected with purified, concentrated and merthiolate-inactivated H₃N₂ influenza virus (kindly provided by Institut Pasteur Production, Paris) in Freund's complete adjuvant (Difco, Detroit, USA) at a dose of 250,000 haemagglutinating units per injection. Following three monthly injections, blood was collected, and the serum titre obtained was 1/25,000 (by haemagglutination inhibition test).

5) *Phagocytosis assay.*

Cytochalasin-B-treated and control SAM were assayed in a phagocytosis test, using *Listeria monocytogenes* as a substrate [6]. Briefly, in a 24-well plastic plate (Falcon 3008, Oxnard, USA), 4 × 10⁵ cells were plated per well. Adherent cells were pretreated with either cytochalasin B or control medium (18 h), and 4 × 10⁶ bacteria were added per well for a 35-min incubation at 37° C. Monolayers were then washed 4 times, cells were lysed by sodium dodecyl sulphate (SDS 0.06 %), and intracellular bacteria were enumerated by colony formation on agar. Each assay was performed in triplicate.

RESULTS

1) *Interactions between influenza virus and SAM in vitro.*

Swine influenza virus induced SAM lysis *in vitro*: this cell lysis was shown by an increased percentage of eosin-stained cells and by a decreased neutral red uptake by infected cells as compared to control cells (table I). This latter coloration test was quantified as described in « Materials and Methods ». Table I provides representative results of 10 experiments, showing that a decreased neutral red uptake occurred following a 24-h virus infection. As incubation with influenza virus proceeded, dead cells detached from the surface. As previously shown [5], when the viral suspension was ultracentrifuged (60 min, 147,000 g) the cytotoxic activity remained associated with the pellet, showing that this activity was supported

by the virus particle. Furthermore, this toxic effect depended upon the viral infective dose: following UV inactivation, the viral suspension lost its lytic effect (table II, representative of 4 experiments).

TABLE. I — Toxicity of influenza virus for SAM « in vitro » as demonstrated by staining monolayers 24 h post-infection with either eosin or neutral red.

Infectivity (EID ₅₀ /well)	Neutral red uptake (OD at 460 nm)	Percentage of dead cells (eosin-stained cells)
0	0.822	4
2.5 × 10 ⁹	0.325	92

TABLE. II — Effect of UV inactivation on influenza virus-induced SAM lysis, as measured 48 h post-infection.

UV inactivation duration (min)	Residual infectivity (EID ₅₀ /well)	OD (460 nm)	
		m	s
—	—	0.57 (*)	0.11
0	10 ⁶	0.13 (*)	0
15	10 ⁵	0.39	0.12
30	10 ⁴	0.51	0.01
120	10 ³	0.61	0.09
240	10	0.65	0

Mean (m) and standard deviation (s) from triplicates.

— = control experiment without virus.

(*) Significantly different ($p < 0.01$ by Student's *t* test).

2) Influence of anti-virus antibodies on influenza virus-induced SAM lysis.

When added to the virus inoculum, pig-influenza antibodies inhibited the virus-induced SAM lysis (table III). This inhibition was not observed with normal pig serum. Such a result may be interpreted in one of two ways: it could mean either that the virus was neutralized by antibodies and was therefore inactivated, or that virus-antibody complexes were more easily phagocytosed by SAM than by virus alone. In order to clarify this point, SAM were pretreated with a phagocytosis inhibitor, cytochalasin B, before virus infection.

3) Effects of cytochalasin B on virus-induced SAM lysis.

SAM pretreated with cytochalasin B (10 µg/ml) were found to have a decreased capacity to phagocytose *L. monocytogenes* within 35 min as compared to untreated cells. Among 4 independent experiments, the extent of inhibition was variable: for example, in one experiment, untreated SAM

TABLE III. — Effects of anti-influenza antibodies on virus-induced SAM lysis.

Experiment No.	Infectivity (EID ₅₀ /well)	Hyper-immune serum	Normal serum	OD (460 nm)	
				m	s
1	0	—	—	0.28	0.01
	2.5 × 10 ⁶	—	—	0.13 (*)	0.01
	2.5 × 10 ⁶	+	—	0.24 (*)	0.03
	2.5 × 10 ⁶	—	+	0.11	0.03
2	0	—	—	0.47	0.12
	10 ⁹	—	—	0.28 (*)	0.01
	10 ⁹	+	—	0.44 (*)	0.03

Final dilution of hyperimmune serum = 1/10.
Final dilution of normal serum (serum obtained before immunization) = 1/10.

Mean (m) and standard deviation (s) of triplicates.

(*) Significantly different (p < 0.01, Student's t test).

TABLE IV. — Effect of cytochalasin B (10 µg/ml) pretreatment of SAM monolayers on their susceptibility to influenza virus-induced lysis (5 × 10⁶ EID₅₀/well).

Pretreatment (18 h)	OD (460 nm)		% control viability
	uninfected	infected	
control medium	m = 0.353 s = 0.021	m = 0.178 s = 0.014	50.5
cytochalasin B	m = 0.445 (*) s = 0.05	m = 0.140 (**) s = 0.013	31.75

OD measured 28 h post-infection.

% control viability = $\frac{\text{OD of infected cells}}{\text{OD of uninfected cells}} \times 100$.

Mean (m) and standard deviation (s) of 4 replicates.

(*) Significantly different from control cells: p < 0.02.

(**) Significantly different from control cells: p < 0.01.

could ingest 3.09×10^3 bacteria within 35 min (Repli. nb = 3, standard deviation (s) = 0.57) whereas cytochalasin-B-treated cells could phagocytose only 1.62×10^3 bacteria (s = 0.50, n = 3, p < 0.05 by Student's t test). Under the same experimental conditions, cytochalasin-B-pretreated SAM monolayers were shown to be more susceptible to lysis by influenza virus than were control cells. Table IV shows representative results of 5 positive assays out of 8 experiments. Cytochalasin B pretreatment appeared to decrease neutral red uptake by infected SAM. Moreover, uninfected SAM were more intensively stained when pretreated with cytochalasin B than were untreated cells. Therefore, these results indicate that a decreased SAM phagocytosis was followed by an increased susceptibility to the virus lytic effect.

DISCUSSION

In the present report, we show that the influenza virus induces SAM lysis *in vitro*: this lytic effect is shown (24 h post-infection) by a decreased neutral red uptake by infected cells as compared to control cells, an increased percentage of eosin-stained cells and a cell detachment from plastic surfaces. We have previously shown that this lysis was due to the virus particle [5]: presently, it appears that UV-inactivated virus suspension is no longer toxic for SAM; furthermore, no viral haemagglutinin or interferon is detectable in infected SAM supernatants (unpublished results). Thus the data indicate that the virus-induced SAM lysis requires a virus infection, but without the production of haemagglutinin by infected cells. These results, obtained with porcine macrophages, are consistent with most studies performed with human or rodent alveolar macrophages. Voisin *et al.* [31] described that the influenza virus (B Lee strain) was phagocytosed by human alveolar macrophages *in vitro* and induced cell death without virus production. With rodent alveolar macrophages, Lemerrier *et al.* [15] showed that infected cells (with the A/PR₈ strain) detached from the plastic surface and exhibited decreased phagocytic capacities. By virus titration, electron microscopy and immunofluorescence, the virus cycle was found to be abortive, with the appearance of viral antigens in infected cells but lack of virus production [15, 17, 19]. Interestingly, Rodgers and Mims [19] observed that mouse peritoneal macrophages were much less susceptible to influenza virus than alveolar macrophages; however, alveolar and peritoneal macrophages were equally restrictive to mouse cytomegalovirus. Interactions between viruses and macrophages differ widely, therefore, according to the virus considered and the anatomical source of the macrophages. In this respect, we observed that although swine influenza virus does not replicate completely in SAM, another virus, namely the porcine coronavirus TGEV (transmissible gastroenteritis virus), does multiply in SAM, inducing cell lysis and interferon production (Laude and Charley, *in press*).

Virus-macrophage interactions can be modified by immune responses [27, 16, 18]: in the case of vaccinia virus, for example, virus uptake by macrophages is enhanced by antibodies, and the neutralized virions are sequestered within lysosomes, where they are degraded [22]. From the present data, it appears that antibodies suppress the SAM lysis by influenza virus: this could mean either that antibodies neutralize extracellular virus particles, or that they opsonize the virus and stimulate its phagocytosis. Since specific antibodies have been shown to enhance influenza virus phagocytosis by human blood leukocytes [3], our results could imply that enhancement of virus phagocytosis could decrease SAM lysis. In order to check this hypothesis, we pretreated SAM with cytochalasin B, a drug which interferes with the microfilament cell functions and decreases phagocytosis [2, 24]. Cytochalasin B was shown to increase the number of glass-adherent rabbit alveolar macrophages [26], and this would explain

why the neutral red uptake was increased in our SAM-pretreated cultures. Furthermore, the latter result shows that cytochalasin B by itself is not toxic for SAM. In our experiments, cytochalasin B slightly decreased *L. monocytogenes* phagocytosis by SAM and reduced neutral red uptake by infected SAM: since cytochalasin B alone did not decrease neutral red uptake, these results suggest that cytochalasin B simultaneously reduced phagocytosis and increased SAM susceptibility to the virus lytic effect. It is therefore proposed that the influenza virus toxic effect could depend upon SAM phagocytic capacities. It has been claimed that the influenza virus is able to penetrate into the cytoplasm through the phagosomes [7]. However, antibodies which promote virus ingestion by macrophages [3, 16] could induce the phago-lysosome fusion so that virus degradation could occur, as reviewed by Elsbach [9]: this would explain why, in our experiments, antibody-virus complexes did not lyse SAM. In the same way, the virus-induced cell lysis appears to be a cytochalasin-B-sensitive phenomenon and therefore related to microfilament cell functions.

From the results presented here, virulent swine influenza virus is shown to be able to lyse SAM *in vitro*, and this lytic effect may be overcome by specific antibodies. Inversely, impaired microfilament functions increase SAM susceptibility to the influenza virus. These data reinforce the idea that specific immune responses, as well as macrophage-activation procedures [21, 10], could help in limiting the harmful consequences of influenza infection by avoiding alveolar macrophage lysis.

RÉSUMÉ

INTERACTIONS ENTRE VIRUS GRIPPAL
ET MACROPHAGES ALVÉOLAIRES DE PORC :
INFLUENCE DES ANTICORPS ANTIVIRAUX ET DE LA CYTOCHALASINE B

Les interactions entre le virus de la grippe porcine et les macrophages alvéolaires de porc ont été étudiées *in vitro*. La lyse cellulaire survient 24 h après l'infection et est mise en évidence par une diminution de l'incorporation de rouge neutre par les macrophages en culture. L'inactivation du virus grippal par les rayons ultraviolets, ou l'addition d'anticorps antiviraux supprime la lyse des macrophages par le virus. A l'inverse, le prétraitement des macrophages alvéolaires de porc par un inhibiteur de phagocytose, la cytochalasine B, accroît la sensibilité des cellules à l'effet lytique viral. Ces études *in vitro* confirment l'hypothèse selon laquelle l'altération des mécanismes pulmonaires antibactériens qui fait suite aux infections grippales est en partie due à un effet toxique direct du virus sur les macrophages alvéolaires. De plus, elles montrent que la lyse des macrophages par le virus est influencée par des réponses immunitaires humorales spécifiques et par des modifications dans les fonctions des microfilaments cellulaires.

MOTS-CLÉS : Phagocytose, Virus de la grippe, Immunomodulation ; Macrophage alvéolaire, Porc, Cytochalasine B, Toxicité virale.

ACKNOWLEDGMENTS

We are grateful to J. Laporte for his help in preparing the manuscript and to E. Petit for her skilful technical assistance.

REFERENCES

- [1] ACTON, J. D. & MYRVIK, Q. N., Production of interferon by alveolar macrophages. *J. Bact.*, 1966, **91**, 2300-2304.
- [2] ALLISON, A. C., DAVIES, P. & DE PETRIS, S., Role of contractile microfilaments in macrophage movement and endocytosis. *Nature (Lond.)*, 1971, **232**, 153-155.
- [3] BOAND, A. V., KEMPF, M. E. & HANSON, R. J., Phagocytosis of influenza virus. — I. *In vitro* observations. *J. Immunol.*, 1957, **79**, 416-421.
- [4] BRICAIRE, F., WILDE, J. L. & HANNOUN, C., Modifications de l'activité bactéricide des leucocytes humains induits par le virus grippal *in vitro*. *Ann. Virol. (Inst. Pasteur)*, 1980, **131 E**, 467-478.
- [5] CHARLEY, B., FRENOVE, B., SALMON, H. & LASCOLS, P., Fc and C₃ receptors on swine alveolar macrophages: effect of swine influenza virus infection. I. P. V. S. Congress, Copenhagen, 1980.
- [6] CHARLEY, B., Le macrophage alvéolaire chez le porc : description et étude fonctionnelle. *Ann. Rech. vét.*, 1982, **13**, 1-8.
- [7] DALES, S., Early events in cell-animal virus interactions. *Bact. Rev.*, 1973, **37**, 103-135.
- [8] DEGRE, M., Synergistic effect in viral-bacterial infection. — 2. Influence of viral infection on the phagocytic ability of alveolar macrophages. *Acta path. microbiol. scand.*, 1970, **78**, 41-50.
- [9] ELSBACH, P., Degradation of microorganisms by phagocytic cells. *Rev. infect. Dis.*, 1980, **2**, 106-128.
- [10] GANGULY, R., CZARUK, K. P., SPENCER, J. C. & WALDMAN, R. H., *In vitro* resistance to influenza virus infection of macrophages induced by BCG. *Indian J. med. Res.*, 1977, **66**, 889-894.
- [11] HANNOUN, C. & GOURREAU, J. M., Surveillance de la grippe chez les porcs sains. *Comp. Immun. Microbiol. infect. Dis.*, 1980, **3**, 133-136.
- [12] HERSCOWITZ, H. B., CONRAD, R. E. & PENNLINE, K. J., Alveolar macrophage-induced suppression of the immune response, in « Macrophages and lymphocytes », Part A (M. R. Escobar & H. Friedman), (p. 459), Plenum Publ. Co. New York, 1980.
- [13] JAKAB, G. J., WARR, G. A. & KNIGHT, M. E., Pulmonary and systemic defenses against challenge with *Staphylococcus aureus* in mice with pneumonia due to influenza A virus. *J. inf. Dis.*, 1979, **140**, 105-108.
- [14] LARSON, H. E. & BLADES, R., Impairment of human polymorphonuclear leucocyte function by influenza virus. *Lancet*, 1976, **I**, 283.
- [15] LEMERCIER, G., MAVET, S., BURCKHART, M. F. & FONTANGES, R., Interactions entre le virus grippal et le macrophage alvéolaire de souris ; étude *in vitro*. *Ann. Microbiol. (Inst. Pasteur)*, 1979, **130 A**, 119-132.
- [16] MORAHAN, P. S. & MORSE, S. S., Macrophage-virus interactions, in « Virus-lymphocyte interactions: implications for disease » (Proffitt), (p. 17-), Elsevier North Holland, Amsterdam, 1979.
- [17] NUGENT, K. M. & PESANTI, E. L., Effect of influenza infection on the phagocytic and bacterial activities of pulmonary macrophages. *Infect. Immun.*, 1979, **26**, 651-657.

- [18] PEIRIS, J. S. M. & PORTERFIELD, J. S., Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. *Nature (Lond.)*, 1979, **282**, 509-511.
- [19] RODGERS, B. & MIMS, C. A., Interaction of influenza virus with mouse macrophages. *Infect. Immun.*, 1981, **31**, 751-757.
- [20] SAWYER, W. D. A., Interaction of influenza virus with leukocytes and its effect on phagocytosis. *J. infect. Dis.*, 1969, **119**, 541-556.
- [21] SHAYEGANI, M., LIEF, F. S. & MUDD, S., Specific and non-specific cell-mediated resistance to influenza virus in mice. *Infect. Immun.*, 1974, **9**, 991-998.
- [22] SILVERSTEIN, S. C., The role of mononuclear phagocytes in viral immunity, in « Mononuclear phagocytes in immunity, infection and pathology ». (R. Van Furth), (p. 557). Blackwell, Oxford, 1975.
- [23] SILVERBERG, B. A., JAKAB, G. J., THOMSON, R. G., WARR, G. A. & BOO, K. S., Ultrastructural alterations in phagocytic functions of alveolar macrophages after parainfluenza virus infection. *J. Reticuloendoth. Soc.*, 1979, **25**, 405-416.
- [24] STOSSEL, T. P., Contractile proteins in phagocytosis: an example of cell surface-to-cytoplasm communication. *Fed. Proc.*, 1977, **36**, 2181-2184.
- [25] STOTT, E. J., PROBERT, M. & THOMAS, L. H., Cytotoxicity of alveolar macrophages for virus-infected cells. *Nature (Lond.)*, 1975, **255**, 710-712.
- [26] SUGIMOTO, M., HIGUCHI, S., ANDO, M., HORIO, S. & TOKUOMI, H., The effect of cytochalasin B on the superoxide production by alveolar macrophages obtained from normal rabbit lungs. *J. Reticuloendoth. Soc.*, 1982, **31**, 117-130.
- [27] TAYLOR, R. N., DIETZ, T. M., MAXWELL, K. W. & MARCUS, S., Effect of influenza virus infection on phagocytic and cytopathic capacities of guinea-pig macrophages. *Immunol. Commun.*, 1974, **3**, 439-455.
- [28] VIRELIZIER, J. L., ALLISON, A. C. & DE MAEYER, E., Production by mixed lymphocyte cultures of a type II interferon able to protect macrophages against virus infections. *Infect. Immun.*, 1977, **17**, 282-285.
- [29] VOISIN, C., MARTIN, G. & AERTS, C., Effets toxiques des virus de la grippe sur les leucocytes de cobaye. *Path. Biol.*, 1960, **8**, 1453-1462.
- [30] VOISIN, C., GUILLAUME, J., AERTS, C., VAN MORLEGHEM, C. & GERNEZ-RIEUX, C., Culture *in vitro* de macrophages alvéolaires de cobaye. Aspects morphologiques en microcinématographie, activités phagocytaire et métabolique. *C. R. Acad. Sci. (Paris)*, 1963, **256**, 3504-3506.
- [31] VOISIN, C., AERTS, C., TONNEL, A. B. & PETITPREZ, A., Action du virus grippal sur les macrophages alvéolaires humains en survie *in vitro*. *Rev. franç. Mal. resp.*, 1974, **2**, 98-104.
- [32] WARR, G. A., JAKAB, G. J. & HEARST, J. E., Alterations in lung macrophage immune receptor(s) activity associated with viral pneumonia. *J. Reticuloendoth. Soc.*, 1979, **26**, 357-366.
- [33] WARSHAUER, D., GOLDSTEIN, E., AKERS, T., LIPPERT, W. & KIM, M., Effect of influenza viral infection on the ingestion and killing of bacteria by alveolar macrophages. *Amer. Rev. resp. Dis.*, 1977, **115**, 269-277.